Household & Personal Products
Compare Stocks
5 / 10Stock Comparison
IPAR vs SKIN vs ELF vs COTY vs ULTA
Revenue, margins, valuation, and 5-year total return — side by side.
Household & Personal Products
Household & Personal Products
Household & Personal Products
Specialty Retail
IPAR vs SKIN vs ELF vs COTY vs ULTA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Household & Personal Products | Household & Personal Products | Household & Personal Products | Household & Personal Products | Specialty Retail |
| Market Cap | $3.03B | $75M | $3.39B | $2.17B | $23.87B |
| Revenue (TTM) | $1.49B | $296M | $1.52B | $5.79B | $12.39B |
| Net Income (TTM) | $201M | $-6M | $104M | $-536M | $1.15B |
| Gross Margin | 64.0% | 64.9% | 70.3% | 61.9% | 39.1% |
| Operating Margin | 18.0% | -3.6% | 11.1% | -0.3% | 39.1% |
| Forward P/E | 19.5x | — | 19.6x | 8.2x | 18.2x |
| Total Debt | $224M | $379M | $313M | $4.25B | $2.18B |
| Cash & Equiv. | $158M | $233M | $149M | $257M | $424M |
IPAR vs SKIN vs ELF vs COTY vs ULTA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Nov 20 | May 26 | Return |
|---|---|---|---|
| Inter Parfums, Inc. (IPAR) | 100 | 174.0 | +74.0% |
| The Beauty Health C… (SKIN) | 100 | 5.7 | -94.3% |
| e.l.f. Beauty, Inc. (ELF) | 100 | 279.9 | +179.9% |
| Coty Inc. (COTY) | 100 | 34.4 | -65.6% |
| Ulta Beauty, Inc. (ULTA) | 100 | 189.4 | +89.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: IPAR vs SKIN vs ELF vs COTY vs ULTA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
IPAR carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 5 yrs, beta 0.61, yield 3.4%
- 256.9% 10Y total return vs ULTA's 150.2%
- Lower volatility, beta 0.61, Low D/E 20.3%, current ratio 2.99x
- Beta 0.61, yield 3.4%, current ratio 2.99x
Among these 5 stocks, SKIN doesn't own a clear edge in any measured category.
ELF ranks third and is worth considering specifically for growth exposure.
- Rev growth 28.3%, EPS growth -13.1%, 3Y rev CAGR 49.6%
- 28.3% revenue growth vs SKIN's -10.0%
COTY is the clearest fit if your priority is value.
- Lower P/E (8.2x vs 19.6x)
ULTA is the #2 pick in this set and the best alternative if valuation efficiency is your priority.
- PEG 0.35 vs IPAR's 0.57
- +34.4% vs SKIN's -53.2%
- 17.3% ROA vs COTY's -4.7%, ROIC 87.9% vs 2.3%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 28.3% revenue growth vs SKIN's -10.0% | |
| Value | Lower P/E (8.2x vs 19.6x) | |
| Quality / Margins | 13.5% margin vs COTY's -9.3% | |
| Stability / Safety | Beta 0.61 vs ELF's 2.27, lower leverage | |
| Dividends | 3.4% yield, 5-year raise streak, vs COTY's 0.6%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +34.4% vs SKIN's -53.2% | |
| Efficiency (ROA) | 17.3% ROA vs COTY's -4.7%, ROIC 87.9% vs 2.3% |
IPAR vs SKIN vs ELF vs COTY vs ULTA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
IPAR vs SKIN vs ELF vs COTY vs ULTA — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ULTA leads in 2 of 6 categories
ELF leads 1 • COTY leads 1 • IPAR leads 1 • SKIN leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ELF leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ULTA is the larger business by revenue, generating $12.4B annually — 41.9x SKIN's $296M. IPAR is the more profitable business, keeping 13.5% of every revenue dollar as net income compared to COTY's -9.3%. On growth, ELF holds the edge at +37.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $1.5B | $296M | $1.5B | $5.8B | $12.4B |
| EBITDAEarnings before interest/tax | $291M | $9M | $235M | $314M | $4.8B |
| Net IncomeAfter-tax profit | $201M | -$6M | $104M | -$536M | $1.2B |
| Free Cash FlowCash after capex | $199M | $29M | $215M | $311M | $986M |
| Gross MarginGross profit ÷ Revenue | +64.0% | +64.9% | +70.3% | +61.9% | +39.1% |
| Operating MarginEBIT ÷ Revenue | +18.0% | -3.6% | +11.1% | -0.3% | +39.1% |
| Net MarginNet income ÷ Revenue | +13.5% | -2.0% | +6.8% | -9.3% | +9.3% |
| FCF MarginFCF ÷ Revenue | +13.3% | +9.7% | +14.1% | +5.4% | +8.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +1.8% | -6.7% | +37.8% | -1.3% | +11.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +2.3% | +38.0% | +116.7% | 0.0% | -5.2% |
Valuation Metrics
COTY leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 18.0x trailing earnings, IPAR trades at a 43% valuation discount to ELF's 31.7x P/E. Adjusting for growth (PEG ratio), ULTA offers better value at 0.39x vs ELF's 0.78x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $3.0B | $75M | $3.4B | $2.2B | $23.9B |
| Enterprise ValueMkt cap + debt − cash | $3.1B | $221M | $3.6B | $6.2B | $25.6B |
| Trailing P/EPrice ÷ TTM EPS | 18.03x | -3.63x | 31.70x | -5.61x | 20.35x |
| Forward P/EPrice ÷ next-FY EPS est. | 19.54x | — | 19.60x | 8.17x | 18.23x |
| PEG RatioP/E ÷ EPS growth rate | 0.53x | — | 0.78x | — | 0.39x |
| EV / EBITDAEnterprise value multiple | 11.39x | 48.65x | 17.59x | 9.32x | 5.29x |
| Price / SalesMarket cap ÷ Revenue | 2.03x | 0.25x | 2.58x | 0.37x | 1.93x |
| Price / BookPrice ÷ Book value/share | 2.75x | 1.29x | 4.67x | 0.54x | 8.37x |
| Price / FCFMarket cap ÷ FCF | 15.88x | 2.02x | 29.41x | 7.83x | 22.35x |
Profitability & Efficiency
ULTA leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
ULTA delivers a 44.1% return on equity — every $100 of shareholder capital generates $44 in annual profit, vs $-14 for COTY. IPAR carries lower financial leverage with a 0.20x debt-to-equity ratio, signaling a more conservative balance sheet compared to SKIN's 6.20x. On the Piotroski fundamental quality scale (0–9), SKIN scores 7/9 vs IPAR's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +18.4% | -9.4% | +8.9% | -14.1% | +44.1% |
| ROA (TTM)Return on assets | +12.9% | -1.2% | +4.5% | -4.7% | +17.3% |
| ROICReturn on invested capital | +18.6% | -6.8% | +13.5% | +2.3% | +87.9% |
| ROCEReturn on capital employed | +23.3% | -4.5% | +16.6% | +2.6% | +107.7% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 7 | 7 | 5 | 6 |
| Debt / EquityFinancial leverage | 0.20x | 6.20x | 0.41x | 1.07x | 0.78x |
| Net DebtTotal debt minus cash | $66M | $146M | $164M | $4.0B | $1.8B |
| Cash & Equiv.Liquid assets | $158M | $233M | $149M | $257M | $424M |
| Total DebtShort + long-term debt | $224M | $379M | $313M | $4.2B | $2.2B |
| Interest CoverageEBIT ÷ Interest expense | 50.40x | 0.79x | 6.48x | 0.23x | 2711.37x |
Total Returns (Dividends Reinvested)
ULTA leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ELF five years ago would be worth $20,957 today (with dividends reinvested), compared to $471 for SKIN. Over the past 12 months, ULTA leads with a +34.4% total return vs SKIN's -53.2%. The 3-year compound annual growth rate (CAGR) favors ULTA at 0.4% vs SKIN's -62.5% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +11.5% | -58.6% | -21.8% | -20.6% | -15.9% |
| 1-Year ReturnPast 12 months | -18.5% | -53.2% | -10.4% | -48.8% | +34.4% |
| 3-Year ReturnCumulative with dividends | -32.3% | -94.7% | -32.4% | -79.6% | +1.1% |
| 5-Year ReturnCumulative with dividends | +47.6% | -95.3% | +109.6% | -72.6% | +61.8% |
| 10-Year ReturnCumulative with dividends | +256.9% | -94.6% | +129.7% | -83.1% | +150.2% |
| CAGR (3Y)Annualised 3-year return | -12.2% | -62.5% | -12.2% | -41.1% | +0.4% |
Risk & Volatility
Evenly matched — IPAR and ULTA each lead in 1 of 2 comparable metrics.
Risk & Volatility
IPAR is the less volatile stock with a 0.61 beta — it tends to amplify market swings less than ELF's 2.27 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ULTA currently trades 73.0% from its 52-week high vs SKIN's 21.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.61x | 1.71x | 2.27x | 1.13x | 0.75x |
| 52-Week HighHighest price in past year | $142.61 | $2.69 | $150.99 | $5.34 | $714.97 |
| 52-Week LowLowest price in past year | $77.21 | $0.57 | $58.05 | $1.96 | $386.00 |
| % of 52W HighCurrent price vs 52-week peak | +66.3% | +21.6% | +40.3% | +46.3% | +73.0% |
| RSI (14)Momentum oscillator 0–100 | 53.4 | 49.5 | 43.1 | 57.9 | 41.8 |
| Avg Volume (50D)Average daily shares traded | 258K | 844K | 2.3M | 7.9M | 719K |
Analyst Outlook
IPAR leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: IPAR as "Hold", SKIN as "Hold", ELF as "Buy", COTY as "Hold", ULTA as "Buy". Consensus price targets imply 124.1% upside for SKIN (target: $1) vs 13.8% for IPAR (target: $108). For income investors, IPAR offers the higher dividend yield at 3.38% vs COTY's 0.62%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Hold | Buy | Hold | Buy |
| Price TargetConsensus 12-month target | $107.50 | $1.30 | $95.17 | $3.90 | $727.36 |
| # AnalystsCovering analysts | 19 | 13 | 27 | 33 | 47 |
| Dividend YieldAnnual dividend ÷ price | +3.4% | — | — | +0.6% | — |
| Dividend StreakConsecutive years of raises | 5 | — | 1 | 1 | 0 |
| Dividend / ShareAnnual DPS | $3.20 | — | — | $0.02 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.5% | 0.0% | +2.0% | 0.0% | +3.8% |
ULTA leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). ELF leads in 1 (Income & Cash Flow). 1 tied.
IPAR vs SKIN vs ELF vs COTY vs ULTA: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is IPAR or SKIN or ELF or COTY or ULTA a better buy right now?
For growth investors, e.
l. f. Beauty, Inc. (ELF) is the stronger pick with 28. 3% revenue growth year-over-year, versus -10. 0% for The Beauty Health Company (SKIN). Inter Parfums, Inc. (IPAR) offers the better valuation at 18. 0x trailing P/E (19. 5x forward), making it the more compelling value choice. Analysts rate e. l. f. Beauty, Inc. (ELF) a "Buy" — based on 27 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — IPAR or SKIN or ELF or COTY or ULTA?
On trailing P/E, Inter Parfums, Inc.
(IPAR) is the cheapest at 18. 0x versus e. l. f. Beauty, Inc. at 31. 7x. On forward P/E, Coty Inc. is actually cheaper at 8. 2x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Ulta Beauty, Inc. wins at 0. 35x versus Inter Parfums, Inc. 's 0. 57x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — IPAR or SKIN or ELF or COTY or ULTA?
Over the past 5 years, e.
l. f. Beauty, Inc. (ELF) delivered a total return of +109. 6%, compared to -95. 3% for The Beauty Health Company (SKIN). Over 10 years, the gap is even starker: IPAR returned +256. 9% versus SKIN's -94. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — IPAR or SKIN or ELF or COTY or ULTA?
By beta (market sensitivity over 5 years), Inter Parfums, Inc.
(IPAR) is the lower-risk stock at 0. 61β versus e. l. f. Beauty, Inc. 's 2. 27β — meaning ELF is approximately 275% more volatile than IPAR relative to the S&P 500. On balance sheet safety, Inter Parfums, Inc. (IPAR) carries a lower debt/equity ratio of 20% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.
05Which is growing faster — IPAR or SKIN or ELF or COTY or ULTA?
By revenue growth (latest reported year), e.
l. f. Beauty, Inc. (ELF) is pulling ahead at 28. 3% versus -10. 0% for The Beauty Health Company (SKIN). On earnings-per-share growth, the picture is similar: The Beauty Health Company grew EPS 55. 6% year-over-year, compared to -609. 8% for Coty Inc.. Over a 3-year CAGR, ELF leads at 49. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — IPAR or SKIN or ELF or COTY or ULTA?
Inter Parfums, Inc.
(IPAR) is the more profitable company, earning 11. 3% net margin versus -6. 2% for Coty Inc. — meaning it keeps 11. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ULTA leads at 39. 1% versus -6. 9% for SKIN. At the gross margin level — before operating expenses — ELF leads at 71. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is IPAR or SKIN or ELF or COTY or ULTA more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Ulta Beauty, Inc. (ULTA) is the more undervalued stock at a PEG of 0. 35x versus Inter Parfums, Inc. 's 0. 57x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Coty Inc. (COTY) trades at 8. 2x forward P/E versus 19. 6x for e. l. f. Beauty, Inc. — 11. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SKIN: 124. 1% to $1. 30.
08Which pays a better dividend — IPAR or SKIN or ELF or COTY or ULTA?
In this comparison, IPAR (3.
4% yield), COTY (0. 6% yield) pay a dividend. SKIN, ELF, ULTA do not pay a meaningful dividend and should not be held primarily for income.
09Is IPAR or SKIN or ELF or COTY or ULTA better for a retirement portfolio?
For long-horizon retirement investors, Inter Parfums, Inc.
(IPAR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 61), 3. 4% yield, +256. 9% 10Y return). e. l. f. Beauty, Inc. (ELF) carries a higher beta of 2. 27 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IPAR: +256. 9%, ELF: +129. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between IPAR and SKIN and ELF and COTY and ULTA?
These companies operate in different sectors (IPAR (Consumer Defensive) and SKIN (Consumer Defensive) and ELF (Consumer Defensive) and COTY (Consumer Defensive) and ULTA (Consumer Cyclical)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: IPAR is a small-cap income-oriented stock; SKIN is a small-cap quality compounder stock; ELF is a small-cap high-growth stock; COTY is a small-cap quality compounder stock; ULTA is a mid-cap quality compounder stock. IPAR, COTY pay a dividend while SKIN, ELF, ULTA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.